English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Correspondence to: Pasi A. Jänne, MD, PhD. Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue; LC4114, Boston, MA 02215, USA. Email: Pasi_Janne@dfci.harvard.edu. Comment on: Baldacci S, Figeac M, Antoine M, et al. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. J Thorac Oncol 2020;15:120-4.

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC